Accolade president Robert Cavanaugh sells $515 in shares

Published 20/11/2024, 21:24
Accolade president Robert Cavanaugh sells $515 in shares

Accolade, Inc. (NASDAQ:ACCD) President Robert N. Cavanaugh recently sold shares of the company's common stock, according to a recent SEC filing. On November 19, Cavanaugh sold 154 shares at an average price of $3.345, totaling approximately $515. This transaction was conducted to cover tax withholding obligations related to the vesting and settlement of restricted stock units (RSUs), as indicated in the filing.

In addition to the sale, Cavanaugh acquired 510 shares of common stock on November 18 through the conversion of RSUs. These transactions left him with a total of 199,502 shares owned directly following the sale. The RSU conversion did not involve any monetary exchange, as each RSU converted into one share of common stock.

These transactions reflect routine financial management by company executives, often conducted to meet tax obligations. Accolade, based in Plymouth Meeting, Pennsylvania, continues to operate in the business services sector.

In other recent news, Accolade Inc (NASDAQ:ACCD). has seen adjustments from Wells Fargo (NYSE:WFC), Stephens, Canaccord Genuity, Truist Securities, and BofA Securities, all reflecting on the company's recent financial performance and future prospects. Wells Fargo revised the price target for Accolade to $6.00, indicating concerns over delayed deal closures potentially affecting revenue growth into Fiscal Year 26 (FY26). Despite this, the firm maintains that Accolade's revenue targets are achievable with moderate growth in Annual Contract Value (ACV).

Stephens also adjusted its price target for Accolade to $8.00, maintaining an Overweight rating and highlighting potential catalysts such as off-cycle large deals and additional revenue from government contracts. Canaccord Genuity, while reducing its price target to $7.00, maintained a Buy rating, expressing confidence in Accolade's ability to meet performance guarantees and secure new business.

Similarly, Truist Securities reduced its price target to $7.50 but maintained its Buy rating on Accolade's stock. BofA Securities followed suit, revising its price target to $5.75, while continuing to hold a Buy rating. These adjustments followed Accolade's strong second-quarter results for 2025, where the company reported revenue of $106.4 million, exceeding expectations, and confirmed its fiscal year 2025 revenue guidance between $460 million to $475 million.

In line with these developments, Accolade's management remains optimistic about a strong pipeline diversified across employers, health plans, and government segments. Despite anticipation of slower revenue growth in fiscal year 2026 due to staggered launches, the company projects a positive adjusted EBITDA of $15 million to $20 million.

InvestingPro Insights

To provide additional context to Accolade's recent insider transaction, let's examine some key financial metrics and insights from InvestingPro.

According to InvestingPro data, Accolade's market capitalization stands at $287.52 million, reflecting its current position in the business services sector. The company's revenue for the last twelve months as of Q2 2025 was $441.03 million, with a revenue growth of 16.04% over the same period. This growth indicates that Accolade is expanding its business operations despite challenges.

An InvestingPro Tip highlights that Accolade's stock price movements are quite volatile, which aligns with the observed 54.56% decline in the stock's price over the past six months. This volatility may explain why executives like Robert N. Cavanaugh engage in stock transactions, potentially as part of their compensation and tax management strategies.

Another relevant InvestingPro Tip notes that Accolade operates with a moderate level of debt, which could be seen as a positive factor in the current economic environment. This moderate debt level may provide the company with financial flexibility as it navigates market challenges and pursues growth opportunities.

For investors seeking a more comprehensive analysis, InvestingPro offers 8 additional tips for Accolade, providing a deeper understanding of the company's financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.